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ABSTRACT
Objective The development of effective visceral
analgesics free of deleterious gut-specific side effects is a
priority. We aimed to develop a reproducible
methodology to study visceral nociception in human
tissue that could aid future target identification and drug
evaluation.
Design Electrophysiological (single unit) responses of
visceral afferents to mechanical (von Frey hair (VFH) and
stretch) and chemical (bradykinin and ATP) stimuli were
examined. Thus, serosal afferents (putative nociceptors)
were used to investigate the effect of tegaserod, and
transient receptor potential channel, vanilloid 4 (TRPV4)
modulation on mechanical responses.
Results Two distinct afferent fibre populations, serosal
(n=23) and muscular (n=21), were distinguished based
on their differences in sensitivity to VFH probing and
tissue stretch. Serosal units displayed sensitivity to key
algesic mediators, bradykinin (6/14 units tested) and ATP
(4/10), consistent with a role as polymodal nociceptors,
while muscular afferents are largely insensitive to
bradykinin (0/11) and ATP (1/10). Serosal nociceptor
mechanosensitivity was attenuated by tegaserod (−20.8
±6.9%, n=6, p<0.05), a treatment for IBS, or
application of HC067047 (−34.9±10.0%, n=7,
p<0.05), a TRPV4 antagonist, highlighting the utility of
the preparation to examine the mechanistic action of
existing drugs or novel analgesics. Repeated application
of bradykinin or ATP produced consistent afferent
responses following desensitisation to the first
application, demonstrating their utility as test stimuli to
evaluate analgesic activity.
Conclusions Functionally distinct subpopulations of
human visceral afferents can be demonstrated and could
provide a platform technology to further study
nociception in human tissue.
INTRODUCTION
Abdominal pain is a common presenting symptom
of GI disease. For many patients, this is a chronic
problem without any clear underlying pathology.
Treating chronic abdominal pain is clinically chal-
lenging due to the lack of efficacy or presence of
gut-specific side effects of many analgesics. As a
result, abdominal pain is a significant factor in the
long-term morbidity associated with many GI dis-
eases, impacting negatively on many quality of life
indicators such as fatigue, sleep and depression.1 2
Conditions characterised by chronic pain are con-
sistently identified as a major burden on the
healthcare system3 underpinning the need to
develop new, safe and effective treatments from
both clinical and socioeconomic perspectives.
Significance of this study
What is already known on this subject?
▸ Dysregulation of peripheral afferent sensitivity
is an important mechanism in chronic visceral
pain; however, current research in this field has
been largely limited to animal models.
▸ Preliminary studies have demonstrated the
feasibility of recording from human GI afferents
in vitro.
▸ Pilot data suggest that subpopulations of
visceral afferents may exist in the human gut.
What are the new findings?
▸ Our studies define the presence of functionally
distinct subpopulations of human visceral
afferents comparable to those seen in animal
studies. Importantly, these include a population of
polymodal nociceptors that preferentially respond
to algogenic stimuli and are located in the serosa.
▸ Human serosal visceral nociceptor
mechanosensitivity is attenuated by treatment
with the transient receptor potential channel,
vanilloid 4 (TRPV4) antagonist (HC067047),
highlighting the therapeutic potential of TRPV4
blockade for the treatment of visceral pain.
▸ Human visceral nociceptor mechanosensitivity
is also attenuated by tegaserod suggesting that
its efficacy for the treatment of pain in IBS may
be mediated through the reduction of visceral
nociceptor mechanosensitivity.
How might it impact on clinical practice in
the foreseeable future?
▸ Data from our studies will allow a greater
understanding of visceral nociceptor function in
health and disease.
▸ The presented methodology provides a platform
for the identification of novel therapeutic
targets and evaluation of novel putative
visceral analgesics.
▸ There is an approach to basic research on
visceral pain that reduces the need for the use
of animal experimentation.
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One approach to analgesic development has been to target
sensory nerves called nociceptors that transduce painful or
noxious stimuli from the periphery to the central nervous
system.4 This approach has therapeutic potential as evidenced
by the effectiveness of local anaesthetics,5 which inhibit periph-
eral input into the pain pathway. A goal of research in this area
has been to identify mechanisms specific to nociceptor activa-
tion that can reproduce the efficacy of local anaesthetics without
the side effects associated with pan-sodium channel blockade. In
particular, the identification of the transient receptor potential
(TRP) family of ion channels as key transducers of noxious
stimuli such as heat, cold and pressure, and as downstream
effectors of receptor activation by inflammatory mediators such
as bradykinin, ATP or prostaglandins, has been the focus of sub-
stantive investigation.6 More recently, the identification of causa-
tive loss-of-function or gain-of-function mutations in specific
sodium channel subtypes (NaV1.7, 1.8, 1.9) selectively
expressed in sensory nerves with clinical pain phenotypes sup-
ports the concept that targeting nociceptor-specific mechanisms
can inhibit pain without affecting other sensory modalities
including touch.7–10
A limitation to research in this area has been our lack of spe-
cific knowledge of human nociceptor function leading to reli-
ance on data from model organisms, principally rodent and
guinea pig. This is particularly true for visceral nociceptors
where current gold standard approaches to studying human
nociceptors such as microneurography,11 or the use of native/
stem cell-derived human sensory neurones are unsuitable.12
This is due to the lack of accessibility of visceral nerves, the
small proportion of visceral nociceptors within sensory
ganglia13 and differences in the transduction of noxious stimuli
by visceral compared with somatic nociceptors.14–17 Surgically
resected human bowel can be obtained on a frequent basis from
consenting patients undergoing surgery as part of their standard
clinical treatment for GI disease. We therefore sought to
develop a methodology to study human nociceptor activity ex
vivo using surgically resected human bowel.
Visceral nociceptors have been extensively characterised in
rodents by their sensitivity to noxious mechanical stimuli (eg,
compression of receptive fields with von Frey hair (VFH) fila-
ments, tissue stretch or high pressure distension),14 18 ischaemic
and hypoxic conditions19 and algogenic mediators (eg, bradyki-
nin and ATP).16 20 This contrasts with other gut afferent popu-
lations that are sensitive to innocuous levels of stretch or light
mucosal stroking and which respond to physiological stimuli
associated with normal movements of the bowel. Visceral noci-
ceptors have been further characterised in model species, includ-
ing rodent and guinea pig, into serosal, mesenteric and
submucosal subclasses based on the location of their receptive
fields in the wall of the gut or mesentery of flat-sheet ex vivo
colonic preparations.14 Pilot data in human tissue suggest
similar subpopulations may exist in man.21 22
To identify and characterise nociceptors in human tissue, we
assessed electrophysiological responses of discriminated visceral
afferent units to the application of mechanical (VFH probing,
tissue stretch and mucosal stroking) and chemical (bradykinin
and ATP) stimuli to their receptive fields. Further, we examined
the effect of tegaserod, a clinically effective treatment of pain in
IBS, and transient receptor potential channel, vanilloid 4
(TRPV4) antagonism, a high value target for the development of
novel visceral analgesics in IBS.23–25 Finally, we sought to
develop a chemosensitivity paradigm in which the efficacy of
other novel analgesics could be tested against noxious inflamma-
tory mediators.
METHODS
All human tissue was collected and used with the approval of
the East London and the City HA Local Research Ethics
Committee (NREC 10/H0703/71). Resected human ileum,
colon, rectum and appendix were collected after written
consent from patients undergoing elective surgery as part of
their standard clinical treatment at the Barts Health NHS Trust
(London, UK). All tissues were obtained from a histopathologist
following pathological examination and used either on the day
of collection (n=57) or after overnight (12–15 hours) cold
storage (4°C) in carbogenated (95% O2, 5% CO2) Krebs buffer
(n=39) (see online supplementary methods).
Electrophysiology
Tissues were transferred to a bespoke rectangular recording
chamber (100 mm (length)×60 mm (width)×20 mm (depth),
with Sylgard base (Dow Corning, UK) and pinned flat with
serosal facing up (figure 1A). Tissues were superfused with car-
bogenated Krebs buffer at a rate of 6 mL/min maintained at 32–
34°C supplemented with atropine (10 mM) and nifedipine
(10 mM) to prevent smooth muscle contractility. Mesenteric
nerve bundles were dissected and recorded using suction elec-
trodes as previously described.22
Experimental protocols
Characterisation of visceral nociceptors
Flat-sheet preparations were assessed for mechanosensitivity by
serosal probing with a blunt cotton bud, longitudinal and/or cir-
cumferential stretch of the tissue with forceps, and in some pre-
parations mucosal stroking with a metal rod. If focal receptive
fields were identified, stimulus-response curves were generated
using a range of increasing strength VFH probes (0.02, 0.04,
0.07, 0.16, 0.4, 1, 2 and 4 g; 3×3 s probe; at 3 s intervals). The
response of mechanosensitive units to the bath application of
algogenic mediators bradykinin and/or ATP was then assessed.
Effects of existing and novel therapeutic treatments for IBS
on visceral nociceptor mechanosensitivity
To confirm the stability of repeated VFH probing, time-matched
control experiments were performed. In these experiments,
three sets (3×3 s) of VFH probes, separated by 5 min intervals,
were performed prior to a 5 min administration of either Krebs
buffer or dimethyl sulfoxide (DMSO) (0.1%) and repeated for
up to an hour thereafter. A similar protocol was then used to
determine the effects TRPV4 modulation on visceral nociceptor
mechanosensitivity by applying the agonist GSK1016790A
(20 mL 10 mM) followed by the antagonist HC067047 (20 mL
100 mM) or in separate studies the 5-hydroxytryptamine (5-HT)
receptor 4 partial agonist tegaserod (100 mL 30 mM) (see
online supplementary methods).
Chemosensitivity of putative nociceptors
In tissues where reproducible mechanosensitivity could not be
determined, chemosensitivity to noxious inflammatory mediators
was examined. In initial studies, bradykinin, ATP, 5-HT, hista-
mine, prostaglandin E2 (PGE2) or capsaicin, were superfused
sequentially into the tissue bath to determine the responsiveness
of each preparation. Next, the response to repeat applications of
bradykinin, ATP, 5-HT, capsaicin or histamine was examined in
separate experiments. A small number of preparations were
tested for mechanosensitivity before and after the application of
bradykinin to test for the recruitment of silent afferents. Finally,
specific bradykinin or ATP receptor agonists (B1 receptor agonist
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Sar-[D-Phe8]-des-Arg9-Bradykinin, P2X receptor agonist α, β
methylene ATP) and antagonists (B1 receptor antagonist R715,
B2 receptor antagonist HOE140, adenosine receptor antagonist
CGS15943, P2×2/3,3 receptor antagonist RO4) were used to
examine the pharmacology of the responses to these mediators.
Post hoc analysis
Post hoc analysis were performed to examine the effect of cold
storage, age, gender and tissue region, on mechanosensitivity
(VFH probing) and chemosensitivity (bradykinin and ATP), in
macroscopically normal tissue from surgical resections per-
formed for the treatment of bowel cancer. Additionally, the
effects of inflammatory disease were examined by comparing
responses with those obtained from inflamed tissue obtained
from resections performed for the surgical treatment of IBD,
Crohn’s disease and UC.
Data analysis
Data analysis has been described previously.22 Neuronal firing
rates were examined offline using data analysis software in Spike
2 (CED, UK). Data sets were analysed using the appropriate
parametric and non-parametric tests; paired and unpaired
t-tests, Fisher’s exact tests and Pearson’s and Spearman’s correla-
tions (see online supplementary methods). Data are expressed as
mean±SEM, and statistical significance was set at p<0.05.
Drugs
Drugs in powder form were solubilised as per the manufac-
turer’s recommendations, aliquoted and frozen at −20°C until
required. Aliquots were diluted in Krebs buffer to final working
concentrations. Bradykinin, GSK1016790A, capsaicin, 5-HT,
histamine, adenosine and ATP were obtained from
Sigma-Aldrich (St Louis, Missouri, USA). HC067047, tegaserod,
HOE140, R715, CGS15943, α,β-methylene ATP,
Sar-[D-Phe8]-des-Arg9-bradykinin and PGE2 were purchased
from Tocris Bioscience (Bristol, UK). RO4 was a gift from
Neusentis (Cambridge, UK).
RESULTS
Characterisation of mechanosensitive units
Forty-six mechanosensitive units were identified in 37/97 pieces
of tissue recorded (online supplementary table S1). Of these,
Figure 1 Characterisation of isolated visceral afferent fibres from resected human bowel tissues into serosal nociceptor and muscular afferent
subtypes based on responses to differing mechanical and noxious chemical stimuli. (A) Example image of resected bowel tissue pinned flat in the
recording chamber. The bowel serosa can be seen below the dissected mesentery. (B) Proportions of muscular and serosal nociceptor subtypes
characterised from identified mechanosensitive afferent recordings. (C) Stimulus-response curve to von Frey hair (VFH) probing (0.02–4 g) for serosal
afferents in resected human bowel tissues. (D) Associated activation thresholds of VFH probing (0.02–4 g). Dashed line at 0.6 g VFH weight
highlights differential activation thresholds of serosal nociceptor (100%) versus muscular subtypes (0%) to VFH probing, potentially allowing
subpopulations to be discriminated by VFH probe threshold alone. (E) Example responses to 0.4 g VFH probe, circular and longitudinal tissue stretch
and stroking of the gut mucosa in both serosal nociceptor and muscular afferent subtypes. Specifically, serosal nociceptors elicit action potential
firing to a range of VFH probe weights tested (0.02–4 g), but are non-responsive to tissue stretch and mucosal stroking. Muscular afferents are
responsive to tissue stretch and only respond to VFH probing at weights of >0.6 g. (F) Examples of action potential firing to prototypic algogenic
mediators bradykinin and ATP in serosal nociceptor and muscular afferents, and the proportion of responders in each afferent subtype.
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two clear subtypes of units could be determined. One subtype
found in 23/46 units tested responded to low weight (threshold
≤0.6 g, 100% of units responded at 0.6 g) VFH probing of the
serosa but not tissue stretch or mucosal stroking, suggesting
localisation within the serosal layer (figure 1B–E). The other
subtype found in 21/46 units tested were responsive to either
circular or longitudinal tissue stretch (13/18 responding to both)
and only responded to high weight VFH probing, if at all
(threshold >0.6 g, only 40% of units responded at 4 g max
weight tested) suggesting they were located in deeper tissue
layers, probably muscle (see figure 1B, D, E and online
supplementary tables S2 and S3). These were termed serosal
and muscular afferents, respectively, in keeping with nomencla-
ture adopted in animal studies.14 One of the 21 muscular units
also responded to mucosal stroking fulfilling the criteria for
muscular-mucosal units. An additional 2 units had receptive
fields in the mesentery fulfilling the criteria for mesenteric units.
The mesentery was not routinely probed due to the danger of
disturbing the recording electrode positioned in the mesentery.
Characterisation of mechanosensitive units by response
to application of algogenic mediators
The potential role of human serosal and muscular units in noci-
ception was examined by testing their responsiveness to proto-
typic algogenic mediators, bradykinin and ATP. Robust
responses were observed to bradykinin in 6/14 serosal units
tested and ATP in 4/10 units tested (figure 1F). By contrast, no
muscular unit responded to bradykinin (0/11) and only one
muscular unit responded to ATP (1/10), indicating that serosal
but not muscular units were likely to function as visceral noci-
ceptors (figure 1F). Consistent with a role as nociceptors the
majority of serosal units (13/23) were silent at rest displaying no
ongoing discharge. By contrast, a significantly greater propor-
tion of muscular units displayed spontaneous activity (17/21,
p<0.05), and this ongoing activity was significantly greater than
that displayed by serosal nociceptors (firing rate muscular 4.1
±0.8 spikes/s vs serosal 0.9±0.2 spikes/s, p<0.01, figure 2).
Mesenteric units also responded to bradykinin and ATP indica-
tive of a role in transducing noxious stimuli.
Additionally, we found evidence for the presence of a ‘silent’
nociceptive population that only displayed mechanosensitivity
to VFH probing following application of bradykinin (n=2,
figure 3 and online supplementary table S4).
Effect of repeat testing and vehicle
We examined the stability of serosal nociceptor responses to
VFH probing and application of vehicle (0.1% DMSO or Krebs
buffer, n=5). Responses to VFH probing were comparable with
baseline (100±9.9%), following vehicle application, for
example, 5 min (109.6±9.4%, p>0.05), 10 min (114.1±9.4%,
p>0.05) and 15 min (106.6±11.5%, p>0.05, figure 4Ai, Aii
and online supplementary table S5) postvehicle, and remained
stable for a further 30 min afterwards (45 min; 84.9±7.2%,
p>0.05), total test period 45 min.
Effect of TRPV4 ligands on visceral nociceptor
mechanosensitivity
Compelling data from animal studies demonstrate a role for
TRPV4 in serosal nociceptor mechanosensitivity,
17 26 suggesting
that TRPV4 antagonists could be effective treatments of visceral
pain. To investigate this further, we examined the effects of
TRPV4 ligands on human serosal nociceptor mechanosensitivity.
Pretreatment with the TRPV4 agonist GSK1016790A had no
effect on mechanosensitivity (n=6, figure 4Bi, Bii and online
supplementary table S6), but significantly increased baseline
activity in 3/8 units tested by ≥50% (see online supplementary
figure S1 and table S7). Strikingly, application of the TRPV4
antagonist HC067047 (at concentrations that attenuates mouse
mechanosensitivity, online supplementary figure S2) significantly
reduced human visceral nociceptor mechanosensitivity (−34.9
±10.0%, n=7, p<0.05), indicating that TRPV4 antagonists may
have utility in the treatment of human visceral pain (see figure
4Ci, Cii and supplementary table S8).
Effect of tegaserod on visceral nociceptor
mechanosensitivity
We examined the effects of tegaserod, a clinically effective treat-
ment of abdominal pain in IBS, on serosal nociceptor mechano-
sensitivity. Tegaserod reduces pain scores in patients with IBS 27
and rectal sensitivity to distension in healthy subjects28 indicat-
ing an inhibitory effect on pain processing. Animal studies
suggest this effect is mediated through a reduction in visceral
afferent activity.29 Tegaserod significantly reduced human
nociceptor mechanosensitivity (−20.8±6.9%, n=6, p<0.05)
suggesting that nociceptor inhibition may contribute to the
clinical effects of tegaserod IBS (see figure 4Di, Dii and online
supplementary table S9).
Chemosensitivity in putative visceral nociceptors
Finally, chemosensitivity was assessed in the remaining prepara-
tions using bradykinin, ATP, capsaicin, 5-HT, histamine and
PGE2 as prototypic algogenic or disease mediators.
30–33 At the
concentrations tested, the frequency of preparations responding
to each mediator ranged from ∼40% to 80% (figure 5). Greater
afferent discharge was observed to mediators typically associated
with the direct production of pain (bradykinin, ATP and
Figure 2 Spontaneous activity in serosal and muscular afferents innervating the human intestine. (A) Pie charts illustrating the proportion of
spontaneously active serosal and muscular units. Muscular afferents were significantly more likely to exhibit spontaneous activity (p<0.01, Fisher’s
exact test). (B) Bar graph demonstrating the firing rate of serosal and muscular units that were spontaneously active. Activity was significantly
greater in muscular compared with serosal afferents (**p<0.01, unpaired t-test). Mean±SEM.
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capsaicin) as opposed to mediators associated with nociceptor
sensitisation (histamine and PGE2) (see figure 5 and online
supplementary table S10). In preparations where single units
could be clearly discriminated, 8/15 units tested responded to
multiple chemical mediators with 4/8 of these units responding
to four or more mediators, highlighting the presence of a spe-
cific subpopulation of afferents with polymodal sensitivity.
Repeat administration
To determine which mediators might be suitable for future
interventional studies, we examined the effect of repeated medi-
ator applications. The response to the first application of brady-
kinin or ATP was greater than subsequent applications, as
previously reported.34 However, after this initial desensitisation,
more consistent responses were obtained to the second and
third applications of bradykinin (second 65.2±9.3% vs third
61.1±9.9%, of the response to the first application, n=6;
online supplementary table S11) or ATP (second 53.8±12.3%
vs third 47.7±10.1% of the response to the first
application, n=4, p>0.05, figure 6A, B and online
supplementary table S12). Responses to a second application of
histamine (1/2, online supplementary table S13) or 5-HT (2/2;
online supplementary table S14) were greatly reduced.
Preparations did not respond to a third application of these
mediators (figure 6C, D). Capsaicin (10 μM) produced a
marked inhibition of ongoing nerve activity following initial
Figure 3 ‘Silent’ afferents were evoked after the application of the algogenic mediator bradykinin (n=2). Rate histograms and neurogram showing
(A) the lack of response to mechanical probing before bradykinin application, (B) the increase in ongoing activity following application of bradykinin
and (C) the acquired mechanosensitivity to von Frey hair probing postbradykinin.
Figure 4 Modulation of mechanosensitive human visceral nociceptors by tegaserod, and the transient receptor potential channel, vanilloid 4
(TRPV4) antagonist HC067047. Example rate histogram and neurogram responses of individual von Frey hair probes at baseline (BL) and from the
set of probes given within the respective minutes illustrated (eg, 5, 10, 15 min) following (Ai) vehicle (0.1% DMSO/Krebs), (Bi) the TRPV4 agonist
GSK1016790A, (Ci) the TRPV4 antagonist HC067047 or (Di) the partial 5-HT4 antagonist tegaserod. Bar graphs illustrating the normalised firing rate
per 2 s probe before and after the application of (Aii) vehicle (0.1% DMSO/Krebs) (n=5), (Bii) GSK1016790A (n=6), (Cii) HC067047 (n=7) or (Dii)
tegaserod (n=6). Mean±SEM. NS, not significant (p>0.05), *p<0.05, paired t-test.
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application. Lower concentrations of capsaicin (100 nM) were
also tested. This concentration did not inhibit baseline activity,
however, only 9 out of 46 units tested responded to two appli-
cations of capsaicin, and the second response to capsaicin typic-
ally showed marked desensitisation. Responses to PGE2 were
considered to be of insufficient magnitude to be of utility in an
interventional paradigm.
Mediator pharmacology
We explored the pharmacology of the bradykinin and ATP acti-
vation of human visceral afferents. Pretreatment with the
selective B2 receptor antagonist HOE140 significantly attenu-
ated the afferent response to bradykinin, while treatment with
the selective B1 antagonist R715 had no effect (second bradyki-
nin additions: control 65.2±9.3% vs HOE140 300 nM 27.2
±6.5%) (n=6, p<0.05; online supplementary table S15) versus
HOE140 1 mM 9.3±8.6% (n=4, p<0.05; online
supplementary table S16) versus R715 81.6±14.9% (n=6,
p>0.05; online supplementary figure S17 and figure 7A,B). The
B1 receptor agonist Sar-[D-Phe8]-des-Arg9-bradykinin had no
effect on human afferent activity (0/14 preparations tested,
online supplementary figure S3A).
Figure 5 Application of algogenic and disease mediators activates visceral afferents innervating the human intestine. Example of rate histograms
illustrating the response profile, and pie charts illustrating the proportion of preparations responding to (A) bradykinin, (B) ATP, (C) capsaicin,
(D) histamine, (E) prostaglandin E2 (PGE2) and (F) 5-hydroxytryptamine (5-HT).
Figure 6 Repeated applications of bradykinin or ATP result in reproducible human afferent responses after initial desensitisation. Bar graphs
illustrating the reproducibility of responses to (A) bradykinin (n=6), (B) ATP (n=4), after initial desensitisation to the first application of the respective
mediator. A proportion of preparations responded to a second application of (C) 5-hydroxytryptamine (5-HT) (2/2) and (D) histamine (1/2), and no
response was seen to a third application of either respective mediator. Mean±SEM. NS, not significant, p>0.05, paired t-test.
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For ATP, pretreatment with the pan-adenosine receptor antag-
onist CGS15943 or the P2X2/3,3 antagonist RO4 did not signifi-
cantly alter the afferent response to ATP (second ATP additions:
control 53.8±12.3% vs CGS15943 81.8±10.6%) (n=6,
p>0.05, online supplementary table S18) versus RO4 100.7
±39.7% (n=3, p>0.05; online supplementary table S19 and
figure 7C, D). However, it should be noted that the P2X recep-
tor agonist α,β-methylene ATP can activate human afferents (1/3
preparations tested, online supplementary figure S3C, D).
Additionally, in one unit which displayed stable responses to
repeated capsaicin administration, incubation with the transient
receptor potential channel vanilloid 1 antagonist ABT-102 abol-
ished the response to a third application of capsaicin. This unit
demonstrated washout to a fourth application of capsaicin (see
online supplementary figure S4).
Post hoc analysis
Finally, we performed a post hoc analysis of single unit
responses to VFH probing, bradykinin and ATP to confirm the
viability of preparations following overnight cold storage; and
elucidate differences based on age, gender or inflammatory
disease. These differences were examined for different regions
of the gut where sufficient data were available.
Afferent responses were comparable following cold storage,
with no significant difference seen in the mechanosensitivity or
chemosensitivity of stored tissues compared with tissue used
immediately (table 1 and online supplementary table S20).
Further data analysis did not reveal any significant difference in
responses based on gender (table 2 and online supplementary
table S21), age (see figure 8 and online supplementary table
S20), tissue region (see table 3 and online supplementary table
S20) or between normal tissue, and tissues obtained from
patients with inflammatory disease (see table 4 and online
supplementary table S22).
DISCUSSION
We present a comprehensive investigation, demonstrating the
feasibility of studying human nerve endings in situ. Our
approach measures action potential firing, the propagating
signal in nociceptors, as opposed to other surrogate markers of
nerve activation (calcium fluxes or transmitter release).
Additionally, we retain the structural complexity of the nerve
terminal architecture in conjunction with local cellular interac-
tions, thereby providing an extension and complementary
approach to existing cell-based methodologies such as use of
isolated human dorsal root ganglia neurons.35 36
We have characterised two functional subtypes of human vis-
ceral afferent fibres innervating the bowel in detail. These are
readily distinguished in a manner analogous to widely used clas-
sifications in rodent nerves.14 Specifically, muscular and serosal
subtypes defined by the sensitivity of the former but not the
latter to tissue stretch, and a clear separation in the activation
threshold to VFH probing between the two subtypes. For
example, serosal units have low intensity VFH thresholds con-
sistent with a superficial location of their receptive fields in the
serosa, while muscular units have a higher threshold suggestive
of a receptive field located deeper in the muscle layers. We also
provide evidence for other functional subtypes, namely mesen-
teric, silent nociceptors and muscular-mucosal afferents suggest-
ing that the modality of sensory signalling from the bowel is
functionally conserved from rodent to human. In addition,
serosal but not muscular afferents were responsive to algogenic
mediators, and possessed a paucity of spontaneous activity sug-
gesting that serosal units were most likely nociceptors, and
Figure 7 Investigation of receptors involved in the activation of afferents innervating the human intestine by bradykinin and ATP. Example of a
rate histogram (A) and bar graph (B) demonstrating the inhibition of human afferent firing in response to bradykinin by pretreatment with the
bradykinin receptor 2 antagonist HOE140 (300 nM, n=6, p<0.05; 1 mM, n=4, p<0.01). In contrast, the bradykinin receptor 1 antagonist R715 (n=6)
failed to inhibit the human afferent response to bradykinin (B). Example of a rate histogram (C) and bar graph (D) showing the lack of human
afferent inhibition in response to ATP when pretreated with the P1 adenosine receptor antagonist CGS15943 (n=6). Similarly, the P2X2/3, 3 receptor
antagonist RO4 (n=3) failed to reduce the human afferent response to ATP (D). Mean±SEM. NS, not significant (p>0.05). *p<0.05, **p<0.01,
paired t-test.
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hence transmit pain from the viscera in response to tissue dam-
aging stimuli. By contrast, muscular units, being responsive to
low threshold stretch of the bowel, are more likely to transduce
physiological stimulation, for example, the passage of bolus
through the gut.
We evaluated the effect of existing and potential therapeutic
treatments for visceral pain on mechanosensitivity to VFH
probing. In keeping with the rodent literature, the application
of TRPV4 agonists or antagonists enhanced or inhibited human
visceral nociceptor activity, respectively.17 Combined with
studies showing endogenous lipid mediators, which stimulate
TRPV4, are elevated in IBS,
25 our data suggest that TRPV4
antagonists could be clinically effective in IBS. Further studies
are needed to confirm these initial findings, particularly using
Table 1 The effect of overnight cold storage on visceral afferent mechanosensitivity and chemosensitivity
Mechanosensitivity
No storage Cold storage
Firing rate spikes 2 s−1 probe (proportion responders) Firing rate spikes 2 s−1 probe (proportion responders)
VFH (g) 0.07 0.4 2 0.07 0.4 2
All tissues 8.6±2.1 (6/10) (60%) 17.7±2.7 (9/10) (90%) 25.7±3.6 (9/9) (100%) 9.5 (1/3) (33%) 18.3±8.2 (3/3) (100%) 15.0±7.0 (2/2) (100%)
Sigmoid colon 9.0±2.3 (3/5) (60%) 22.3±3.3 (4/5) (80%) 29.6±4.9 (5/5) (100%) 9.5 (1/3) (33%) 18.3±8.2 (3/3) (100%) 15.0±7.0 (2/2) (100%)
Rectum 7.8±7.3 (2/3) (67%) 15.7±6.4 (3/3) (100%) 24.2±5.4 (3/3) (100%) – – –
Bradykinin
Proportion responders Δ Firing rate (spikes 20 s−1) Proportion responders Δ Firing rate (spikes 20 s−1)
All tissues 19/26 (73%) 51.7±10.5 5/13 (39%) 37.7±8.1NS
Sigmoid colon 8/13 (62%) 67.3±19.2 4/10 (40%) 32.3±8.4NS
Rectum 4/6 (67%) 34.4±18.6 1/1 (100%) 54
ATP
Proportion responders Δ Firing rate (spikes 20s−1) Proportion responders Δ Firing rate (spikes 20 s−1)
All tissues 14/14 (100%) 30.5±8.0 9/12 (75%) 30.2±7.8NS
Sigmoid colon 8/8 (100%) 32.4±10.9 6/8 (75%) 33.2±12.7NS
Rectum 3/3 (100%) 31.3±18.6 1/1 (100%) 20
Table illustrating single unit responses to VFH probing at 0.07, 0.4 and 2 g, bradykinin or ATP in tissues used on the day of operation or following cold storage. The data were analysed
for tissue from cancer resections only, and presented for all tissue regions studied, sigmoid colon only and rectum only. Mean±SEM; p>0.05; paired t-test.
NS, not significant; VFH, von Frey hair.
Table 2 The effect of gender on visceral afferent mechanosensitivity and chemosensitivity
Mechanosensitivity
Male Female
Firing rate spikes 2 s−1 probe (proportion responders) Firing rate spikes 2 s−1 probe (proportion responders)
VFH (g) 0.07 0.4 2 0.07 0.4 2
All tissues 11.8±1.4 (4/9) (44%) 18.1±3.4 (8/9) (89%) 21.5±4.5 (7/7) (100%) 4.7±2.1 (3/4) (75%) 17.4±4.8NS (4/4) (100%) 27.6±4.7NS (4/4) (100%)
Sigmoid colon 11.5±2.0 (2/6) (33%) 19.1±4.7 (5/6) (83%) 21.4±5.4 (5/5) (100%) 6.8±0.3 (2/2) (100%) 24.3±6.8 (2/2) (100%) 35.5±2.5 (2/2) (100%)
Rectum 15 (1/1) (100%) 26 (1/1) (100%) 33 (1/1) (100%) 0.5 (1/2) (50%) 10.5±1.0 (2/2) (100%) 19.8±0.8 (2/2) (100%)
Bradykinin
Proportion responders Δ Firing rate (spikes 20 s−1) Proportion responders Δ Firing rate (spikes 20 s−1)
All tissues 15/23 (65%) 58.5±12.0 9/16 (56%) 30.2±5.9NS
Sigmoid colon 8/15 (53%) 69.6±22.1 4/8 (50%) 36.9±7.3NS
Rectum 3/3 (100%) 52.6±20.9 2/4 (50%) 16.9±12.3
ATP
Proportion responders Δ Firing rate (spikes 20 s−1) Proportion responders Δ Firing rate (spikes 20 s−1)
All tissues 17/18 (94%) 35.4±6.4 6/8 (75%) 13.8±3.2NS
Sigmoid colon 12/13 (92%) 35.3±8.4 2/3 (67%) 10.4
Rectum 2/2 (100%) 43.9±23.9 2/2 (100%) 13.0±6.4
Table illustrating single unit responses to VFH probing at 0.07, 0.4 and 2 g, bradykinin or ATP in tissues from male or female patients. The data were analysed for tissue from cancer
resections only, and presented for all tissue regions studied, sigmoid colon only and rectum only. Mean±SEM; p>0.05; paired t-test.
NS, not significant; VFH, von Frey hair.
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TRPV4 ligands from alternative chemotypes
17 26 to support
selectivity of action over other TRP family members.37 38 We
also demonstrated an inhibitory effect of tegaserod on human
visceral nociceptor mechanosensitivity illustrating how our
studies provide information on the reverse translation of
clinically effective drugs, in addition to supporting rodent data
suggesting a peripheral site of action of tegaserod.
Chemosensitivity was assessed to a range of noxious,
inflammatory mediators in preparations in which defined
mechanosensitive units could not be identified. We chose to
examine responses to capsaicin and bradykinin as prototypic
noxious mediators that elicit pain following local injection in
humans.19 20 ATP was examined, due its release from the
viscera following inflammation or distension and algesic effects
following dermal injection in humans,30 31 while 5-HT, PGE2
and histamine were selected due to their increased production
in the bowel of patients with IBS32 and clinical efficacy of
agents modulating their pharmacology.39 The goal of these
studies was to evaluate the effect of each mediator on visceral
afferent signalling, and develop an alternative experimental
protocol which could be used to investigate the analgesic
potential of novel therapeutic approaches. We showed a subpo-
pulation of fibres are sensitive to a range of mediators, indicat-
ing that drugs which block convergent points in the activation
of nociceptors by multiple algogenic mediators are needed.4
We also examined the stability of repeated mediator application,
highlighting the suitability of bradykinin and ATP for use as test
stimuli. Afferent responses to capsaicin, histamine and 5-HT
showed progressive desensitisation to repeat application, and
capsaicin also inhibited ongoing nerve activity. The inhibitory
effect of capsaicin is consistent with its clinical use in topical
creams, which treat pain by desensitising nociceptors.40 By con-
trast, the pathophysiological implications of desensitising
responses to 5-HT and histamine is unclear given the clinical
efficacy of 5-HT3 antagonists and histamine H1-receptor
antagonists in IBS, and may be a feature of this experimental
system.41 42
Further investigation confirmed that bradykinin stimulates
human visceral afferent activity via B2 receptors consistent with
rodent data.15 43 While responses to repeated application of
ATP were not sensitive to blockade with a selective P2X2/3
antagonist (RO4) or pan-P1 adenosine receptor antagonist
Figure 8 The effect of age on visceral afferent mechanosensitivity and chemosensitivity. Scatter plots illustrating afferent responses to (A) von Frey
hair probing at 0.4 and 2 g, (B) bradykinin or (C) ATP compared with the patient’s age. Responses were plotted for tissues from cancer resections
only, and presented for all tissue regions studied and sigmoid colon only. Pearson’s or Spearman’s correlations were performed based on data
normality.
Table 3 The effect of tissue region on visceral afferent mechanosensitivity and chemosensitivity
All tissues Sigmoid colon Rectum
Mechanosensitivity VFH (g)
Firing rate spikes 2 s−1 probe
Proportion responders
Firing rate spikes 2 s−1 probe
Proportion responders
Firing rate spikes 2 s−1 probe
Proportion responders
0.07 8.8±1.8
7/13 (54%)
9.1±1.6
4/8 (50%)
7.8±7.3
2/3 (67%)
0.4 17.8±2.7
12/13 (92%)
20.6±3.7
7/8 (88%)
15.7±5.2
3/3 (100%)
2 23.7±3.3
11/11 (100%)
25.4±4.6
7/7 (100%)
24.2±4.4
3/3 (100%)
Chemosensitivity
Δ Firing rate spikes 20 s−1
Proportion responders
Δ Firing rate spikes 20 s−1
Proportion responders
Δ Firing rate spikes 20 s−1
Proportion responders
Bradykinin 49.1±8.6
24/39 (62%)
57.7±14.7
12/23 (52%)
38.3±14.9NS
5/7 (71%)
ATP 30.3±5.4
23/26 (88%)
32.8±7.9
14/16 (88%)
28.5±13.5NS
4/4 (100%)
Table illustrating single unit responses to VFH probing at 0.07, 0.4 and 2 g, bradykinin or ATP in tissues from different tissue regions. The data were analysed for tissue from cancer
resections only. Mean±SEM;p>0.05; paired t-test.
NS, not significant; VFH, von Frey hair.
94 McGuire C, et al. Gut 2017;67:86–96. doi:10.1136/gutjnl-2016-311629
Neurogastroenterology
group.bmj.com on January 29, 2018 - Published by http://gut.bmj.com/Downloaded from 
(CGS15493), suggesting the response to ATP in our experimen-
tal paradigm was largely driven by P2Y receptor activation, con-
sistent with recent findings in mouse and human tissue.44
Importantly, our work does not preclude the activation of
human visceral afferents by P2X2/3 or P1 receptors. We have
found excitatory responses to the P2X2/3 agonist, α,β-methylene
ATP (see online supplementary figure S3B–D), highlighting the
redundancy and complexity of purinergic signalling.
Post hoc analysis of mechanosensitivity and chemosensitivity
demonstrated stability to overnight cold storage of tissue, sug-
gesting that tissue could be transported over distance to recipi-
ent laboratories. Additionally, no significant differences were
seen in responses analysed by age, gender or tissue region, sug-
gesting that the function of individual fibres may not be greatly
affected by these variables. This does not exclude the possibility
that differences exist. For example, the tissue region used may
be important as the anatomical innervation by vagal, splanchnic
and pelvic afferent nerves is markedly different between regions
of the gut and functional responses to different stimuli can
vary.45 However, we applied specific stimuli that preferentially
targeted spinal nociceptors consistent with a lack of regional dif-
ferences in responses. In addition, the recent demonstration of
reduced visceral afferent sensitivity to noxious stimuli in aged
mice,46 and reduced afferent activity with age in human
tissue,47 48 highlights the need for further studies on visceral
nociception in human tissue.
A further consideration with the use of human tissue is the
diversity of patients’ backgrounds. This will result in greater vari-
ability of responses compared with tissue from experimental
animals, making small changes difficult to see without large
sample numbers. Our tissue is obtained from patients with disease,
which may polarise patient demographics compared with the
populace as a whole. This is particularly apparent in the age and
gender of the patients, for example, the majority of our normal
tissues came from male patients aged between 50 and 70 years,
and our female tissues comes from postmenopausal women.
Finally, our findings in diseased human tissue (IBD) demon-
strate how this approach will provide insight into the patho-
physiology of naturally occurring disease. Our data set does not
support a marked change in sensitivity of visceral afferents in
IBD, although clearly more work is needed to understand if this
is related to disease or an effect of patient treatments, for
example, the use of steroids or antitumour necrosis factor anti-
bodies which could have an effect on afferent signalling.49 50
The use of human visceral nociceptor recordings has great
future potential enabling further investigation of the physiology
of human nociceptor stimulus transduction, the pharmacology
of nociceptor signalling and as a translational platform for the
validation and identification of future novel visceral analgesics.
As highlighted, a pragmatic approach needs to be taken when
using human tissue, particularly when interpreting negative find-
ings; however, there is clear value in using human tissue to
study specific, well-designed, research questions on human vis-
ceral nociceptor function.
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